Status:
RECRUITING
Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
NSCLC (Non-small Cell Lung Cancer)
Eligibility:
All Genders
18+ years
Brief Summary
First discovered in 1997 the torque teno virus (TTV) can be found in the vast majority of the human population throughout their lifetime. The TTV levels correlate with infectious diseases and organ re...
Eligibility Criteria
Inclusion
- \- Histologically or cytologically verified NSCLC stage II-IV (OMD) according to UICC TNM8 edition considered operable in curative intent after neoadjuvant systemic therapy containing immune checkpoint inhibition by local multidisciplinary tumor board (MDT) decision.
- ECOG \< or = 1 Staging with PET/CT and cMRI/CCT Written informed consent
Exclusion
- \-
Key Trial Info
Start Date :
September 6 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06967532
Start Date
September 6 2024
End Date
September 1 2026
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090